Chronic Migraine Without Aura, Intractable, Migraine Disorders, Migraine With Typical Aura
Conditions
Keywords
Migraine, Craniofacial Neuralgia
Brief summary
The purpose of the study is assessment of the safety and efficacy of the De-Novo therapy in the treatment of craniofacial neuralgia and migraine headaches.This is an open-label study of simultaneous administration of combination of dexamethasone, lidocaine, and thiamine into the trigeminal nerve branches as well as greater and lesser occipital nerve bilaterally in one session. Patients who meet the exclusion and inclusion criteria are eligible for trial if they have experienced chronic migraine and craniofacial pain not responding to other prior therapies.
Detailed description
A combination of dexamethasone, lidocaine and thiamine (pat.), may bring changes in the pattern of sympathetic and parasympathetic nerve signaling at the level vasa nervorum. These changes may down-regulate the hyperexcitable sympathetic signals at the level of adventitia and consequently the medial layer of vasa nervorum and providing long term relief from migraine headaches. However, a bilateral and simultaneous treatment of trigeminal and occipital nerves in migraine and craniofacial neuralgia using a combination of dexamethasone, thiamine and lidocaine has been rarely studied. The objective of this study is to assess the safety and efficacy of concomitant administration of dexamethasone, lidocaine, and thiamine compounds into the trigeminal nerve branches, the greater and lesser occipital nerve for the treatment of chronic migraine, and craniofacial neuralgia.
Interventions
COMBINATION_PRODUCTDexamethasone, Lidocaine, Thiamine cohort
Bilateral and simultaneous administration of composition of De-Novo Treatment Cohort medication (Dexamethasone, Lidocaine, Thiamine) into the trigeminal and greater/lesser occipital nerves in one session.In children and hypersensitive individuals with needle phobia pre-treatment of skin with Lidocaine 2.5% Prilocaine 2.5% cream, and oral Alprazolam 0.25 mg (an Anxiolytic) 2 hours prior to initiation of procedure will be used.
Sponsors
Corona Doctors Medical Clinics, Inc.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Prospective Open Label Study
Eligibility
Sex/Gender
ALL
Age
10 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
* • Age: 10-90 years * Ability to describe headache and its symptoms * Ability to read, comprehend, and legibly and reliably record information * Ability to provide written, informed consent, and respond to pre and post treatment questionnaires, children's guardian accepts responsibility. Willingness and ability to comply with the study scheduled visits, treatment plans, laboratory tests and other procedures * Already diagnosed with chronic craniofacial neuralgia and chronic migraine headache * Exhausted all or most of available abortive and preventive treatment modalities.
Exclusion criteria
* • Uncontrollable hypertension, acute Myocardial Infarct within last 6 months * History of cerebral vascular aneurysm/known atherosclerosis of cerebral system, brain tumor * Implanted of neuro-stimulator, trigeminal tractotomy, neurectomy partial or complete, history of gamma knife treatment, microsurgical decompression procedure. * Hypersensitivity or allergy to any components of De-Novo formula * Presence or known anatomic craniofacial deformities or severe spondylosis/spondylolisthesis of cervical spine, profound dental caries, Maxillofacial deformities * Pregnancy and current breast feeding status * Headaches attribute to acute head and neck injuries, chronicity of cervicogenic headaches * Skin infection or micro abscesses dermatogen or dental, ongoing treatment for Methicillin Resistant Streptococcus Aureus ( MRSA) unless treatment completed.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Assessment of the safety to the De-Novo treatment formula in study patients | 5 weeks | Study assesses the safety of the De-Novo algorithm( if patients who receive this treatment will experience any major adverse reactions due to the medication combination )within the next 5 weeks following treatment. Participants will be interviewed after the initial treatment weekly, for 5 weeks to evaluate for any possible adverse events, hospitalization, or treatment. Any significant adverse event in over 45% of participants, may project end of the trial. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Assessment of the clinical response to the De-Novo treatment formula in study patients consisting of a lone composite measure | 12 months | Assessment of the clinical response to the De-Novo treatment formula in study patients. Study assesses the efficacy parameters of the study ( i.e. the change in baseline frequency of migraine attack in patients post initial treatment ), and functionality status based on continuation of work performance and return to work or school. Therefore, the Outcome of study consisting of multiple measures and present lone composite measure. |
Countries
United States
Contacts
Primary ContactFaro T. Owiesy, M.D.
Backup ContactJovana Martin Murillo
Outcome results
None listed